This site is intended for U.S. Healthcare Professionals only.

  • U.S. Full Prescribing Information |
  • Medication Guide |
  • Indication

    Indication

    SOTYKTU is indicated for the treatment of moderate-to-severe plaque psoriasis in adults who are candidates for systemic therapy or phototherapy.

    Limitations of Use: SOTYKTU is not recommended for use in combination with other potent immunosuppressants.

This website is best viewed
using the horizontal display
on your tablet device.

This website is best viewed
using the vertical display
on your mobile device.

Advocacy for your practice
and patients

Stay up-to-date on the latest news from advocacy groups and connect with
other professionals.

Advocacy for your practice
and patients

Stay up-to-date on the latest news from advocacy groups and connect with
other professionals.

Getting started

Advocacy groups

You should always be the go-to person to discuss your patients’ moderate-to-severe plaque psoriasis. After all, you understand their individual goals.

However, sometimes they need a little more information. That’s why we’re including a few additional resources that may be valuable to you and them.

The Autoimmune Association
The Autoimmune Association is the world’s leading nonprofit organization dedicated to autoimmune awareness, advocacy, education, and research.
NPF
NPF is the leading national nonprofit organization supporting research on psoriasis and psoriatic arthritis and advocating for the needs of the psoriatic disease community.
The Global Healthy Living Foundation (GHLF)
The Global Healthy Living Foundation (GHLF) seeks to inspire, support, and empower people living with
chronic illnesses. They offer evidence-based
education and tools that help people living with
serious and often lifelong conditions.
Bristol Myers Squibb™ Logo

SOTYKTU, SOTYKTU 360 SUPPORT, and SOTYKTU
logo
are trademarks of Bristol-Myers Squibb Company.

Otezla is a registered trademark of Amgen Inc.

© 2023 Bristol-Myers Squibb Company.

1787-US-2300483 07/23

1787-US-2300303 06/23

1787-US-2300737 10/23

1787-US-2300483 07/23

1787-US-2300303 06/23